Meiji Seika Pharmatech Co., Ltd.

Tokyo, Japan
Small Molecule (oral solid dose — tablets, fine granules, capsules) β-Lactam Antibiotics (dedicated containment) Sterile Injectables (vials, pre-filled syringes) Vaccines / New Modalities Generics (including HPAPI up to OEL Category 4)
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Meiji Seika Pharmatech Co., Ltd.

Signal Score
60.0/100
Quality Compliance
Assessment pending
Headquarters
Tokyo, Japan
Modalities
Small Molecule (oral solid dose — tablets, fine granules, capsules), β-Lactam Antibiotics (dedicated containment), Sterile Injectables (vials, pre-filled syringes), Vaccines / New Modalities, Generics (including HPAPI up to OEL Category 4)
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Meiji Seika Pharmatech Co., Ltd.

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesSmall Molecule (oral solid dose — tablets, fine granules, capsules), β-Lactam Antibiotics (dedicated containment), Sterile Injectables (vials, pre-filled syringes), Vaccines / New Modalities, Generics (including HPAPI up to OEL Category 4)
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (5 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Broad modality coverage (5 modalities)
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Small Molecule (oral solid dose — tablets, fine granules, capsules) CDMOs → β-Lactam Antibiotics (dedicated containment) CDMOs → Sterile Injectables (vials, pre-filled syringes) CDMOs → Vaccines / New Modalities CDMOs → Generics (including HPAPI up to OEL Category 4) CDMOs →